Germany approved a plan in mid-August to legalize some recreational cannabis.
According to a recent New York Times (1) article, the German government signed off on legislation that would allow adults to buy and possess small amounts of cannabis, but parliament still needs to approve the measure.
It is currently illegal to buy cannabis in Germany, but not illegal to consume it. The endorsement from the three-party coalition’s cabinet was a crucial step toward Germany becoming the first major European country to legalize marijuana (1).
The approved legislation would reportedly allow adults to purchase and possess up to 25 grams of recreational cannabis for personal consumption through nonprofit social clubs (1). This plan would allow distribution through the creation of licensed private cultivation associations with no more than 500 members. Members would be allowed to buy up to 25 grams a day, but with a limit of 50 grams in a month (1).
“This is an important law that will represent a long-term change in drug policy,” said Karl Lauterbach, Germany’s health minister, at a news conference on August 16, 2023 (1).
The German government also reportedly plans to launch a series of regional pilot programs that would allow the sale of cannabis through a small number of licensed specialty shops to gather more information about the effects of allowing individuals to purchase the plant commercially. Similar pilot programs exist in the Netherlands and Switzerland.
Germany is not alone in their interest to legalize cannabis in some form. Several other European countries have expressed interest in cannabis legislation, such as the Czech Republic, Prague, Luxembourg, and Switzerland (2). Malta was the first country to legalize cannabis in the European Union (EU). Despite challanges from conservative members of the EU, it will be interesting to see how these countries handle cannabis legalization moving forward.
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.